Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Sernova

Market Cap 58.53M 41.8M 36.04M 33.16M 31.18M 3.96B 59.23M 391M 152M 1.94B 157M 154M 6.71B P/E Ratio 2026 *
-4.67x
P/E Ratio 2027 * -3.5x
Enterprise Value 58.53M 41.8M 36.04M 33.16M 31.18M 3.96B 59.23M 391M 152M 1.94B 157M 154M 6.71B EV / Sales 2026 *
-
EV / Sales 2027 * 11.7x
Free-Float
86.83%
Yield 2026 *
-
Yield 2027 * -
1 week+3.33%
Current month+10.71%
3 months-8.82%
6 months+10.71%
Current year+19.23%
1 week 0.14
Extreme 0.14
0.16
1 month 0.14
Extreme 0.135
0.17
3 years 0.12
Extreme 0.12
1.1
5 years 0.12
Extreme 0.12
2.22
10 years 0.1
Extreme 0.095
2.87
Manager TitleAgeSince
Chief Executive Officer 58 2024-08-11
Director of Finance/CFO 60 2024-10-10
Investor Relations Contact - 2024-10-10
Director TitleAgeSince
Director/Board Member 60 2012-04-18
Director/Board Member - 2023-04-23
Director/Board Member - 2024-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-9.68%+3.33%-6.06%-81.98% 41.88M
+0.86%+3.00%-17.68%+5.05% 118B
0.00%-0.70%+3.38%-9.59% 12.9B
-2.01%+4.57%+30.67%+88.96% 7.64B
-1.56%-2.13%-48.07%-72.02% 4.17B
-1.32%+4.41%+11.37%+31.99% 2.57B
-2.22%+8.61%-18.14%-17.65% 1.78B
-1.85%-8.17%+1.21%-17.07% 1.63B
+2.62%-6.01%+157.24%+127.66% 1.36B
Average -0.68%+1.91%+12.66%+6.15% 18.76B
Weighted average by Cap. +0.49%+2.02%-11.98%+6.96%

Financials

2026 *2027 *
Net sales - 5M 3.57M 3.08M 2.83M 2.66M 338M 5.06M 33.44M 13.01M 166M 13.41M 13.12M 573M
Net income -12.83M -9.16M -7.9M -7.27M -6.83M -867M -12.98M -85.79M -33.38M -426M -34.4M -33.67M -1.47B -19.77M -14.12M -12.17M -11.2M -10.53M -1.34B -20.01M -132M -51.46M -656M -53.03M -51.9M -2.27B
Net Debt - -
Logo Sernova
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
-
Date Price Change
26-06-16 0.1400 $ -9.68%
26-06-15 0.1550 $ +6.90%
26-06-12 0.1450 $ -6.45%
26-06-11 0.1550 $ +3.33%
26-06-10 0.1500 $ 0.00%
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1550CAD
Average target price
0.4500CAD
Spread / Average Target
+190.32%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!